Last reviewed · How we verify
Hypoalphalipoproteinemia
Approved treatments
- Inosital
Inosital works by influencing the metabolism of lipids in the body. - Zocor · Merck & Co.
- Myoinositol · University of Colorado, Denver
- Tricor (Micronized) · Salix
Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion. - Trilipix · AbbVie
- Mevacor · Merck & Co.
Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hypoalphalipoproteinemia patent landscape — cliff calendar, originator estates, attackable patents
- Hypoalphalipoproteinemia treatment landscape brief
- Hypoalphalipoproteinemia treatment updates RSS
Frequently asked questions about Hypoalphalipoproteinemia
What drugs treat Hypoalphalipoproteinemia?
Tracked treatments include Inosital, Zocor, Myoinositol, Tricor (Micronized), Trilipix, Mevacor.
What is the treatment for Hypoalphalipoproteinemia?
Standard treatment for Hypoalphalipoproteinemia includes Inosital, Zocor, Myoinositol, Tricor (Micronized), Trilipix. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hypoalphalipoproteinemia patent cliff · Hypoalphalipoproteinemia CI report
- Treatment: Inosital
- Treatment: Zocor · Merck & Co.
- Treatment: Myoinositol · University of Colorado, Denver
- Treatment: Tricor (Micronized) · Salix
- Treatment: Trilipix · AbbVie
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing